Prion Protein Targeted by a Prostate Cancer Cell Binding Aptamer, a Potential Tumor Marker?
Tao BingJunyan WangLuyao ShenXiangjun LiuDihua ShangguanPublished in: ACS applied bio materials (2020)
Cell-SELEX is an effective strategy to discover aptamers that can distinguish the molecular signatures of target cells from control cells. The molecular targets of such aptamers have the potential to be biomarkers. Here, we report target identification of aptamer wy-5a generated by cell-SELEX against a prostate cancer cell line, PC-3. This aptamer specifically binds PC-3 cells and a doxorubicin-resistant breast cell line, MCF-7R, as well as tissue sections of prostate cancer with high risk of metastasis. Prion protein was identified to be the molecular target of wy-5a by stable isotope labeling with amino acids in cell culture (SILAC)-based quantitative proteomic method. The octapeptide repeat region of prion protein was demonstrated to be the binding site of aptamer wy-5a. The expression levels of prion protein in cancer tissues were further tested by immunohistochemical staining of tissue sections from 48 prostate cancer patients and 98 breast cancer patients. The results suggest that prion protein has the potential to be one of the referenced markers of prostate and breast cancers.
Keyphrases
- prostate cancer
- amino acid
- radical prostatectomy
- single cell
- gold nanoparticles
- binding protein
- protein protein
- label free
- poor prognosis
- induced apoptosis
- stem cells
- gene expression
- cancer therapy
- oxidative stress
- magnetic nanoparticles
- risk assessment
- high resolution
- drug delivery
- mesenchymal stem cells
- human health
- endoplasmic reticulum stress
- long non coding rna
- climate change
- mass spectrometry
- cell proliferation